Diabetic Macular Edema

Diabetic retinopathy can cause swelling of the center of the retina, the macula, and vision loss.

What is a Diabetic Macular Edema

Diabetic macular edema is swelling in the retina associated with diabetes. This swelling can blur and distort the vision. The swelling occurs because the walls of the small blood vessels are progressively more damaged in diabetes, and there is leakage of blood and fluid into the cells of the retina. There are a variety of options to treat diabetic macular edema. The oldest treatment is laser for retinal swelling. It has been studied for decades and has been shown to be safe and effective. As with all treatments, it is not curative, and it is not without risk, but laser is one of the safest things that we do in diabetic retinal care. Other newer treatments for diabetic retinal swelling have been shown to improve vision even more than laser in some cases, and have also been shown to be safe and effective in large modern trials. These treatments are a variety of injections given into the eye in the office, and they are sometimes given alone and sometimes given with laser in addition. There are two major classes of injections used in diabetic macular edema, and those are small molecule injections and corticosteroid injections. The injections work in different ways to reduce the leakage and swelling in the retina, and sometimes the different types of injections are both used. The injections are administered under local anesthesia, and are often relatively well-tolerated by patients. Injections are also amongst the safest procedures performed in the retinal clinic, and the specific risks and benefits of injections will be discussed by your doctor. Most patients with blurred vision from diabetic macular edema enjoy an improvement in vision with treatment. Often, treatment to maintain vision is ongoing, and the long-term treatment plan is individualized to each specific patient in our practice.

What is a Laser?

When diabetic macular edema is caused by focal areas of leakage, laser treatment can be helpful. Studies were done in the 1980's validating the use of laser to reduce the risk of vision loss and improve vision in patients with diabetic macular edema. The advantage of laser of intravitreal injections is that laser treatment usually only needs to be repeated a few times. Intravireal injections are given monthly. The disadvantage of laser, is that it does not improve vision as much as intravitreal injections do when the center of the macula is swollen. Many physicians will use both laser and intravitreal injections depending on the area of the macula that is swollen and the findings on examination and testing.

Lucentis for Diabetic Macular Edema

Monthly Lucentis therapy is helpful for patients with diabetic macular edema. With laser only, about 15 percent of patients have substantial visual improvement at 2 years. With Lucentis therapy, about 40 percent of patients have a substantial improvement in visual acuity. Subsequent studies have shown that ongoing monthly treatment is usually not necessary to maintain the visual benefit.


Diabetic Macular Edema NEWS

Below are current articles from a Google News Feed on Diabetic Macular Edema

Protocol V Sheds Light on Managing Mild Diabetic Macular Edema  Medscape

Until now, data have been relatively scarce on the optimal treatment timing for patients who have diabetic macular edema with good vision.

Retinal angiographic alteration in diabetic macular edema after dexame | IMCRJ  Dove Medical Press

Retinal angiographic alteration in diabetic macular edema after dexamethasone implantation: a case report.

Vrinda Hershberger, MD, PhD: Faricimab for Diabetic Macular Edema  MD Magazine

Additional analyses of the phase 2 BOULEVARD trial, which found faricimab not only led to improved best-corrected visual acuity and central subfield thickness ...

Anti-VEGFs pose no additional risk of SAEs over other therapies  Modern Retina

Anti-vascular endothelial growth factor (VEGF) therapy does not increase the risk of systemic serious adverse events in patients with diabetic macular edema ...

Deep learning model detects diabetic eye diseases accurately  Medical Xpress

According to the research findings published in Scientific Reports, the deep learning model detects the severity grade of diabetic retinopathy and macular ...

Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema  GlobeNewswire

ATLANTA, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of ...

Using AI to Identify Diabetic Retinopathy and Clinically Significant DME  MD Magazine

Artificial intelligence could be the future of detecting certain diseases in the eye, after a study presented at ASRS 2019 found that the EyeArt system was effective ...

Fewer visits needed with combined suprachoroidal triamcinolone, aflibercept for DME  Healio

CHICAGO — Patients with diabetic macular edema treated with suprachoroidal triamcinolone in combination with aflibercept achieved similar vision in fewer ...

Non-infectious Macular Edema Treatment Market 2019 Europe and Japan Industry Analysis, Size, Share, Upcoming Trends, Segmentation and Forecast to 2025 |  Medgadget

Europe and Japan Non-infectious Macular Edema Treatment Market: Europe and Japan Size, Trends, Competitive, Historical & Forecast Analysis,

Anti-VEGFs as a Treatment for Diabetic Retinopathy and PANORAMA Results  MD Magazine

W. Lloyd Clark, MD, of Palmetto Retina Center, discusses clinical implications of the 52-week PANORAMA results, which found treatment with intravitreal ...

FDA Approves Aflibercept Injection Treatment for Retinal Conditions  MD Magazine

The new FDA approval allows physicians to administer EYLEA in a prefilled syringe to treat retinal conditions with fewer preparation steps than vials.

Combination of intravitreal bevacizumab and erythropoietin vs intravitreal bevacizumab alone for refractory diabetic macular edema: A randomized double-blind clinical trial  MD Linx

Internal Medicine Article: Combination of intravitreal bevacizumab and erythropoietin vs intravitreal bevacizumab alone for refractory diabetic macular edema: A ...

Laser therapy maintains position as key DME treatment option  Ophthalmology Times

Laser continues to play an important role in diabetic macular edema amid an increasing reliance on anti-VEGF drugs. Reviewed by Elias Reichel, MD.

VIDEO: Steroid challenge predictive of IOP lowering in eyes with fluocinolone implants  Healio

CHICAGO — At the American Society of Retina Specialists meeting, Victor H. Gonzalez, MD, summarizes a trial on the real-world use of Iluvien (fluocinolone ...

W. Lloyd Clark, MD: Choosing Between Anti-VEGF Treatments  MD Magazine

Physician from Palmetto Retina Center on deciding between aflibercept, ranibizumab, and avastin for treatment of DME.

2019 Diabetic Macular Edema Market Analysis, Size, Share, Trends, Segmentation & Forecast to 2025  Rise Media

ReportsnReports added a new report on The Diabetic Macular Edema Market report delivers the clean elaborated structure of the Report comprising each and ...

Effect of intravitreal dexamethasone solution on the reduction of macu | OPTH  Dove Medical Press

Effect of intravitreal dexamethasone solution on the reduction of macular thickness in pseudophakic diabetic patients in a public hospital in Brazil: a randomized ...

Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe  Yahoo Finance

Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.

Global trends show similar patterns worldwide  Modern Retina

The ASRS Global Trends Survey finds differences in some treatment preferences.

VIDEO: Faricimab shows long-term durability potential as DME treatment  Healio

CHICAGO — At the American Society of Retina Specialists meeting, Vrinda S. Hershberger, MD, PhD, discusses her presentation on the anatomical and ...

Lipid-lowering medications are associated with lower risk of retinopathy and ophthalmic interventions among United States patients with diabetes  MD Linx

In this retrospective cohort analysis, researchers assessed the effect of lipid-lowering medications on diabetic retinopathy and diabetic complications requiring ...

Watchful waiting reasonable for patients with diabetic macular edema and good vision: Starting treatment prior to vision loss unnecessary for most people; close monitoring essential  Science Daily

People with good vision despite having center-involved diabetic macular edema can safely forego immediate treatment of their eye condition as long as they are ...

Alimera Sciences Announces Multiple Papers “On Demand” at the 2019 American Society of Retina Specialists Annual Meeting  GlobeNewswire

ATLANTA, July 23, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of ...

Kodiak's AMD med posts promising phase 1b data in 3 eye diseases  FierceBiotech

Eylea and Kodiak's KSI-301 are both anti-VEGF biologics injected into the eye. But KSI-301 has a longer half-life, meaning that patients could go longer between ...

A better strategy for treating diabetic macular edema in people with good vision  EurekAlert

BOSTON - (April 29, 2019) - A change to the approach for treating diabetic macular edema may be on the way, thanks to a study published today in the Journal ...

Short-Term Effects of Ranibizumab Biosimilar Compared to Ranibizumab for DME  MD Magazine

A study presented at ASRS 2019 found that the ranibizumab biosimilar (razumab) was noninferior to ranibizumab after 1 month of treatment.

Watchful Waiting OK in Diabetic Macular Edema With Good Vision  Medscape

Among patients with center-involved diabetic macular edema (CI-DME) who had good visual acuity, there were no significant differences in vision loss over a ...

Diabetic Macular Edema Market Projected to Register a Sluggish Expansion through 2027  The Trusted Chronicle

The global diabetic macular edema (DME) market is projected to register a sluggish expansion at 1.1% CAGR through 2027, according to a report by Future ...

FDA Action Alert: Regeneron, Kala and Vanda  BioSpace

Now that July has come and gone, the U.S. Food and Drug Administration is back to work approving drugs. This week marks three PDUFA target action dates, ...

Drugs offer activation combination of Tie2 pathway in DR, DME  Modern Retina

May provide better anatomic improvement, decreased DR severity scores.

A Patient’s Guide to Eye Disease  U.S. News & World Report

Learn about common eye diseases, as well as the symptoms, causes and treatment options, at U.S. News and World Report.

Macular Edema Treatment Market Growth Till, 2018-2026: Coherent Market Insights  Business Intelligence

Macular edema is the condition characterized by abnormal leakage and accumulation of fluid that forms blister in the layer of macula. The macula is an ...

Optical coherence tomography patterns of diabetic macular edema in a S | OPTH  Dove Medical Press

Optical coherence tomography patterns of diabetic macular edema in a Saudi population Sanaa A Yassin,1 Saud M ALjohani,1 Arwa Z Alromaih,2 Abdulaziz A ...

Global Diabetic Macular Edema Drug Market Size, Share, Growth Analysis for Future Scope, trend and Diversity 2022  Bridgeport Daily

The Report on Global Diabetic Macular Edema Drug Market provides a professional Outlook of Industry and breakdown data by manufacturers, region, type and ...

Real World Patterns of Diagnosis, Progression, and Treatment in Patients with Diabetic Retinopathy Over Five Years  DocWire News

Over five years, patients with an initial diagnosis (ID) of moderate and severe nonproliferative diabetic retinopathy (NPDR) were more likely to develop diabetic ...

Interesting Sessions to Come at ASRS 2019  MD Magazine

Here's a primer for new data and discussions MD Mag will be covering this weekend in Chicago.

Global Diabetic Macular Edema Treatment Market an estimated worth value of 3.9 billion in 2025.| Novartis AG, GlaxoSmithKline plc, Alimera Sciences, ALLERGAN, Regeneron Pharmaceuticals Inc., Pfizer Inc.  US Trade Media

Global Diabetic Macular Edema Treatment Market Report provides top to bottom examination of the market as far as income and developing business sector is ...

RECOVERY trial looks at retinal nonperfusion area with monthly, quarterly aflibercept  Healio

CHICAGO — Eyes with proliferative diabetic retinopathy treated with monthly aflibercept experienced a stable retinal nonperfusion area after 1 year compared ...

Research initiatives offer treatment options for diabetes patients  Optometry Times

The Diabetic Retinopathy Clinical Research Network (DRCR.net) supports the identification, design, and implementation of multicenter clinical research ...

Last trial OKed for Eylea to prevent blindness in premature infants  Korea Biomedical Review

The Korean drug regulator has approved a phase-3 clinical trial on Eylea (ingredient: aflibercept), an anti-vascular endothelial growth factor (anti-VEGF) ...

Diabetic Macular Edema Drug Market Size from 2019-2025 | Novartis, Bayer, Allergan, Hoffman-La Roche, Alimera, Valeant  The Tribune Today

This Global Diabetic Macular Edema Drug market elaborate report, compiled by Market Research Globe, offers a summary study on regional forecast, business ...

VIDEO: Study quantifies benefit of sustained-release implant in DME  Healio

CHICAGO — At the American Society of Retina Specialists meeting, Christopher P. Riemann, MD, discusses his study seeking to quantify the advantages of ...

Opthea's Patent Application Covering OPT-302 to be Granted by European Patent Office  GlobeNewswire

MELBOURNE, Australia, July 30, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce that the European Patent Office (EPO) has ...

Subfoveal choroidal thickness in diabetic macular edema | OPTH  Dove Medical Press

Dalia Mohamed Fawzy Mohamed,1 Nihal Adel Hassan,2 Amr Abdellatif Osman,2 Moataz Hamed Osman2 1Department of Ophthalmology, National Institute of ...

Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update  BioSpace

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, ...

W. Lloyd Clark, MD: Ways to Improve Noncompliance  MD Magazine

W. Lloyd Clark, MD, discusses the approaches he uses in his clinical practice to reduce patient noncompliance — specifically, when treating diabetic macular ...

Global Integrin Beta 3 Market 2019 – Melanoma, Arterial Thrombosis, Diabetic Macular Edema, Lung Cancer, Others  Market Reports

Worldwide Global Integrin Beta 3 2019 market size Value (USD Million) for historical period (2015 – 2018) and projected years (2019 – 2025). The Global ...

Bicycle Therapeutics Reports Second Quarter 2019 Financial Results and Provides Clinical Update  BioSpace

Provides update on the Phase I/IIa trial evaluating lead asset BT1718 in patients with advanced solid tumors; Successfully completed initial public offering (IPO) ...

New report on Diabetic Macular Edema Market 2019-2025 worldwide growth expected by top players Allergan, Novartis, Regeneron Pharmaceuticals, Pfizer, Bayer AG  Market Expert

Diabetic macular edema, an ophthalmologist checks the retina for symptoms of the disease including leaking blood vessel, retinal swelling, damaged nerve ...

TMR's Recent Publication includes an Extensive Analysis on the Ocular Drug Delivery Technology Market  ScoopJunction

This report on the Global Ocular Drug Delivery Technology market analyzes the current and future scenario of the global market. Rise in private and public ...

Dexamethasone implant in the management of diabetic macular edema from | OPTH  Dove Medical Press

Mojca Urbančič,1 Ivana Gardašević Topčić2 1Eye Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia; 2Department of Ophthalmology, General ...

Type 2 diabetes: The sign in your eyes you should never ignore - are you at risk?  Express

TYPE 2 diabetes is a common condition that causes the level of sugar in the blood to become too high. A person's eyesight might hold the key to whether they ...

Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance  Nasdaq

Aerie Pharmaceuticals, Inc . AERI reported better-than-expected results for the second quarter of 2019. However, the company lowered its annual.

Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?  Yahoo Finance

Regeneron Pharmaceuticals, Inc. REGN is scheduled to release second-quarter 2019 results on Jul 6, before the opening bell. In the last reported quarter, the ...

Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMD  GlobeNewswire

OPT-302 Combination Therapy Demonstrated Superiority in Visual Acuity over Lucentis®. Company to Host Conference Call Today at 9:00 AM AEST 7:00PM ...

Diabetic Macular Edema Clinical Trials Review, H1, 2019 Market: Future Scenarios and Business Opportunity Analysis 2025  Market Reporter

In 2025, the market size of the Automotive Fleet Management Market is expected to touch million US$ xx million. The revenue registered in 2018 was US$ xx ...

Diabetic Macular Edema Treatment Market by Product Type, Application and Geography – Forecast to 2022  Market Reporter

The Diabetic Macular Edema Treatment Market report 2019 deeply analyses significant features in major developing markets. The analysis includes market size, ...

Opthea to Host Investor Teleconference Australian Stock Exchange:OPT.AX  GlobeNewswire

MELBOURNE, Australia, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) will host a conference call to discuss the results of the Company's ...

Clearside Biomedical Announces Multiple Oral Presentations Delivered at the American Society of Retinal Specialists (ASRS) Annual Meeting  Yahoo Finance

Clearside had a widespread presence at the ASRS Annual Meeting with multiple presentations and publications on our XIPERE™ data, the use of ...

Allegro Ophthalmics to Present for the First Time the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the ASRS Annual Meeting 2019  Yahoo Finance

Risuteganib Met Visual Acuity Primary Endpoint with Statistical Significance in U.S. Phase 2 Trial.

Roche Study Shows AI Can Detect Severity of Diabetic Macular Edema  BioSpace

The study showed that artificial intelligence can be used to provide widespread, cost-effective eye screenings via telemedicine to assist ophthalmologists in ...

Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting  BioSpace

Published: Jul 24, 2019. Initial Phase 1b data for KSI-301 in Wet AMD, DME, and RVO to be presented. PALO ALTO, Calif., July 24, 2019 /PRNewswire/ ...

Diabetic Macular Edema Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2025  Outlook Biz

An extensive study offering forecast assessment on Diabetic Macular Edema Market has been broadcasted. By correlating the historical data with key market ...

Characteristics of diabetic macular edema on optical coherence tomogra | OPTH  Dove Medical Press

Characteristics of diabetic macular edema on optical coherence tomography may change over time or after treatment Shwu-Jiuan Sheu,1,2 Ying-Yen Lee,1 ...

Cytomegalovirus Retinitis Treatment Market Analysis and Global Research Report 2019  Market Research Feed

Cytomegalovirus Retinitis Treatment Market research report is prepared by a bunch of market professionals with a zeal to deliver a high quality business report.

Diabetic macular edema: the strategy for monitoring it in people who still have good vision  SciTech Europa

The research, published in the Journal of the American Medical Association. The study found that people with diabetic macular edema, who still have good ...

Global Diabetic Macular Edema Treatment Market 2019: Size, Share, Scope, Growth Opportunities Analysis By Top key players like-Regeneron Pharmaceuticals Inc., Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd., Oculis, Bayer AG  Tribaux

Global Diabetic Macular Edema Treatment Market has been accelerated as the prevalence of diabetes causes Macular Edema in patients. With this trend Global ...

Diabetic Macular Edema Treatment Market Comprehensive Analysis With Key Trends in Infectious and Rare Diseases sector, Major Drivers And Challenges 2019-2023  Market Reporter

Diabetic Macular Edema Treatment Market research report is a compilation of insight data on market size, market growth trends that will help research Institutes, ...

UNITY Biotechnology, Inc. Reports Second Quarter 2019 Financial Results and Program Updates  GlobeNewswire

SAN FRANCISCO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing ...

Retinal Disease Therapeutics Market Increase CAGR at 8.6%, Analysis, Revenue, Growth Rate Forecast till 2026  Ghanasoccernet.com

The Global Retinal Disease Therapeutics Market is likely to expand at an impressive rate driven by recent government participation towards the prevention and ...

IRIDEX to Report Second Quarter 2019 Financial Results on August 6, 2019  Yahoo Finance

MOUNTAIN VIEW, Calif., July 23, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter ...

Non Infectious Macular Edema Treatment Market to Create Lucrative Opportunities for Existing Companies as Well as New Players  Herald Space

The ophthalmology sector has gained massive traction during the course of the last few years. This is a result of growing prevalence of diseases like macular ...

Anti-VEGF Effective in Persistent Diabetic Macular Edema  Medscape

A recent analysis associated three different anti-VEGF agents with meaningful vision gains through 2 years of follow-up.

Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference  GlobeNewswire

REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior ...

Diabetic Macular Edema Market Size, Share and Manufacture Development Analysis Report 2027  Amazing Newspaper

Diabetic Macular Edema refers to accumulation of fluid in the macula that controls the vision abilities due to blood vessel leakage. It is mainly identified as a ...

Research to Prevent Blindness and American Academy of Ophthalmology Award Grants for Big Data Research to Improve Patient Care  Newswise

The American Academy of Ophthalmology and Research to Prevent Blindness today announced this year's recipients of the RPB/AAO Award for IRIS® Registry ...

EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists  GlobeNewswire

WATERTOWN, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company ...

Global Diabetic Macular Edema Treatment Market at a CAGR of 1.4% in the forecast by 2018-2025 | Industry Analysis by Pfizer Inc. Alimera Sciences, ALLERGAN, Regeneron Pharmaceuticals Inc.  industryreports24.com

Global Diabetic Macular Edema Treatment Market research report is of the one of the real business strategies embraced by the key players.Global Diabetic ...

EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS)  GlobeNewswire

WATERTOWN, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company ...

Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option  GlobeNewswire

REDWOOD CITY, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company ...

Global Macular Edema Therapeutics Market Analysis Report 2019-2024: Allergan, Novartis, Roche, Regeneron Pharmaceuticals, Pfizer, Bayer  News Industry 24

The “Macular Edema Therapeutics Market” research report gives details about the Macular Edema Therapeutics market, its size, segments, financial growth, ...

LORATI Successfully Develops Effective Treatment for Diabetic Macular Edema Using Eye Drops  PRNewswire

TAIPEI, Taiwan, May 14, 2019 /PRNewswire/ -- Lorati Company Limited, a Taiwan-based biotechnology and pharmaceutical company, today announced that it ...

Difference in Treatment Effect Between Intravitreal Aflibercept Injection and Laser by Baseline Factors in Diabetic Macular Edema  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effect of baseline factors on differences in vision gains with ...

Diabetic Macular Edema Treatment Market Size | Industry Report, 2025| Genentech, Novartis, GlaxoSmithKline, Eyetech Pharmaceuticals  Weekly Wall

Los Angeles, United State, July 24, 2019, – The latest report published by QY Research presents a thorough analysis of the global Diabetic Macular Edema ...

Global and Regional Diabetic Macular Edema Treatment Market Report with Major Vendor Landscape and Their Strategies and CAGR of 1.45%  The Rent Fint

TheDiabetic Macular Edema Treatment Marketreport2019deeply analyses significant features in major developing markets. The analysis includes market size, ...

Risuteganib complements anti-VEGF treatment for diabetic macular edema  Healio

VIENNA — Integrin inhibitor risuteganib was effective in complementing the anti-VEGF pathway when administered sequentially to an anti-VEGF drug in patients ...

Case Report on DME | Medpage Today  MedPage Today

An unexpected resolution of diabetic macular edema.

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 37th Annual Scientific Meeting of the American Society of Retina Specialists  Yahoo Finance

WATERTOWN, Mass., July 23, 2019 -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and ...

EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress  GlobeNewswire

Company reports total revenue of $7.2 million –. – Two commercial product launches in U.S. are underway for DEXYCU® and YUTIQ® with 43 sales reps ...

Diabetic Macular Edema (DME) Market Insight, Size, Assessment, Opportunities, Patent Data, Pathophysiology and Diagnostic Trends, and Forecast  PortNews24

“Diabetic Macular Edema (DME): Market Assessment, Epidemiology & Market Forecast-2028” report provides an overview of the disease and market size of ...

Experimental drug delivers one-two punch to vision loss: Experiments show new therapy slows blood vessel leakage associated with diabetic macular edema and macular degeneration  Science Daily

In studies with lab-grown human cells and in mice, researchers have found that an experimental drug may be twice as good at fighting vision loss as previously ...

DIABETIC MACULAR EDEMA TREATMENT MARKET TO EXHIBIT SIGNIFICANT OPPORTUNITY ASSESSMENT DURING THE FORECAST PERIOD (2017 – 2025)  Financial Planning

Diabetic macular edema (DME) is characterized by accumulation of fluid in the macula – a part of retina responsible for vision. Accumulation may cause by ...

KalVista: Cheap, Well-Funded, And Headed Towards Key Catalysts  Seeking Alpha

KalVista's valuation continues to drift but it has two things going for it: cash runway & catalysts. With ~$100M in cash & investments, KalVista is funded into.

Now Available Diabetic Macular Edema Drug Market Forecast And Growth 2019-2025  Market Mirror

The “Diabetic Macular Edema Drug Market” globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has ...

Double-Barreled Biologic for Diabetic Retinopathy Emerging  Medscape

Trial results for the first biologic to target both the VEGF and Ang-2 pathways designed for less frequent injections than current options will be presented at the ...

Type-2 diabetes symptoms: Patients must never ignore this sign in their eyes  Daily Star

TYPE-2 diabetes symptoms include rapid weight loss and extreme thirst. But here's one important sign people must never ignore.

Do Corticosteroids Improve Diabetic Macular Edema Outcomes?  Medscape

Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 ...

Protocol V trial results favor observation strategy for DME with good vision  Healio

The DRCR.net Protocol V clinical trial concludes that patients with center-involved diabetic macular edema and good vision can confidently be managed by ...

Two-year analysis of changes in the optic nerve and retina following a | OPTH  Dove Medical Press

Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients Richard Filek,1 Phil Hooper2,3, ...

FDA Approves Aflibercept for Diabetic Retinopathy  MD Magazine

Aflibercept (Eylea) is an anti-VEGF treatment administered as an intravitreal injection.

» Load more